Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK105550)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA217987)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01 AI153167)
Received: 1 September 2021
Accepted: 26 May 2022
First Online: 16 June 2022
: E.M.W. receives research funding from Boehringer-Ingelheim and is a member of their myositis ILD advisory board. A.R.S. and I.S.G. are co-founders of AbSeek Bio. R.H.C. is an inventor on patents related to other SARS-CoV-2 antibodies. J.E.C. has served as a consultant for Luna Biologics, is a member of the Scientific Advisory Boards of CompuVax and Meissa Vaccines and is Founder of IDBiologics. J.E.C. has received sponsored research agreements from Takeda Vaccines, IDBiologics and AstraZeneca. J.M.I. was a co-founder and a board member of Cytobank Inc. and has engaged in sponsored research with Incyte Corp, Janssen, Pharmacyclics. J.C.R. is a founder, scientific advisory board member, and stockholder of Sitryx Therapeutics, a scientific advisory board member and stockholder of Caribou Biosciences, a member of the scientific advisory board of Nirogy Therapeutics, has consulted for Merck, Pfizer, and Mitobridge within the past three years, and has received research support from Incyte Corp., Calithera Biosciences, and Tempest Therapeutics. No other author declares any competing interests.